<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448758</url>
  </required_header>
  <id_info>
    <org_study_id>CB(NPC)²-1209</org_study_id>
    <nct_id>NCT02448758</nct_id>
  </id_info>
  <brief_title>Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)</brief_title>
  <acronym>CB(NPC)²</acronym>
  <official_title>Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Biologie Pathologie : Plateforme de Biologie Moléculaire de Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to create a database at the regional level, the principle is to
      include all patients in whom a mutation was detected from a single platform (Lille). The
      creation of this regional cohort, smaller than the national cohort of Biomarkers France, will
      perform a more comprehensive collection of clinical data, and molecular monitoring data of
      patients included. To increase the completeness of the collection of information, it will not
      be based on voluntary prescribing clinician but will be largely carried out by CRA dedicated
      to this activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective and retrospective study of a population of patients with mutated
      non-small cell lung cancer in the Nord Pas de Calais. Retrospective cohort will involve
      patients with main molecular abnormalities, identifiable from molecular biology platform
      CRRC, except EGFR and KRAS treated from September 2011 to February 2013.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between clinical factors and mutation status</measure>
    <time_frame>at baseline</time_frame>
    <description>The clinical factors are age, smoking status, occupational and environmental exposure, personal and family background, TNM stage, performance status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients included in a clinical trial dedicated to a certain type of non-small cell lung cancer with mutation</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases per mutation type</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">785</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Non-small cell lung cancer with mutation of the Nord Pas de Calais
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 18 years old

          -  Patient with non-small cell lung cancer

          -  Detected in the Nord Pas de Calais

          -  Monitored in the Nord Pas de Calais

          -  Patient must have signed a non-opposition form to the use of medical data

        Exclusion Criteria:

        - No identified mutation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis CORTOT, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHRU of Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Dansin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexis CORTOT, MD, PhD</last_name>
    <phone>+33 3 20 44 56 12</phone>
    <email>alexis.cortot@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Dansin, MD</last_name>
    <phone>+33 3 20 29 59 20</phone>
    <email>e-dansin@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Dansin, MD</last_name>
      <phone>+33 3 20 29 59 20</phone>
      <email>e-dansin@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Eric DANSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Cortot, MD,PhD</last_name>
      <phone>+33 3 20 44 56 12</phone>
      <email>alexis.cortot@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Alexis CORTOT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

